



Compare three diagnostic criteria of progressive pulmonary fibrosis

Tao Chen, Chunfang Zeng

Department of Respiratory and Critical Care Medicine, People's Hospital of Deyang City, Deyang, China

Contributions: (I) Conception and design: T Chen; (II) Administrative support: C Zeng; (III) Provision of study materials or patients: Both authors; (IV) Collection and assembly of data: T Chen; (V) Data analysis and interpretation: T Chen; (VI) Manuscript writing: Both authors; (VII) Final approval of manuscript: Both authors.

Correspondence to: Tao Chen, MD; Chunfang Zeng, MD. Department of Respiratory and Critical Care Medicine, People's Hospital of Deyang City, No. 173, Taishan North Road, Deyang 618000, China. Email: 18817598314@126.com; 717142334@qq.com.

Background: In patients with fibrotic interstitial lung disease (ILD), a progressive pulmonary fibrosis (PPF) typically demonstrates worsening respiratory symptoms, lung function decline and continuing fibrosis. The goal of this study was to compare the three different diagnostic criteria of PPF.

Methods: Except for idiopathic pulmonary fibrosis (IPF), all consecutive adult patients with fibrotic ILD were retrospectively examined for the three predefined diagnostic criteria of PPF. The three criteria assessed the disease progression in preceding 6 (0.5-year), 12 (1-year) and 24 (2-year) months respectively. The clinical characteristics, decline in predicted percent of forced vital capacity (FVC%) and survival of three groups were compared, followed by determination of risk factors for mortality.

Results: We identified 246 patients by 0.5-year standard, 154 patients by 1-year standard and 281 patients by 2-year standard. Among them, 95% of patients in 1-year group were also included in 2-year group. The average 1-year decline in FVC% was -1.0%, -2.7%, and -4.1% for 0.5-, 1-, and 2-year group respectively. The 4-year survival rate was 74% in 0.5-year group, 66% in 1-year group, and 62% in 2-year group. In multivariate Cox model, only baseline predicted percent diffusing capacity of the lungs for carbon monoxide ($DL_{CO}\%$) <50% was correlated with mortality, with a hazard ratio of 3.4 (95% CI: 1.1–10.6, $P=0.03$).

Conclusions: In the current situations, both the 1- and 2-year criterion are the reasonable choice to define PPF both in researches and clinical practice, and $DL_{CO}\%$ is an independent predictor for mortality of PPF.

Keywords: Progressive pulmonary fibrosis (PPF); diagnostic criteria; risk factors; mortality

Submitted Jun 11, 2023. Accepted for publication Dec 08, 2023. Published online Feb 27, 2024.

doi: 10.21037/jtd-23-481

View this article at: <https://dx.doi.org/10.21037/jtd-23-481>

Introduction

Fibrotic interstitial lung disease (ILD) consists a heterogenous group of diseases characterized by varying degree of pulmonary interstitial inflammation and fibrosis (1). Idiopathic pulmonary fibrosis (IPF) is the most prevalent ILD featured with progressive fibrosing interstitial pneumonia with unknown causes. Apart from IPF, about 13–40% percent of patients with non-IPF fibrotic ILD also experience progressive deterioration in interstitial fibrosis and lung function (2,3), which is defined as progressive

pulmonary fibrosis (PPF). PPF typically demonstrates worsening respiratory symptoms, lung function decline, continuing fibrosis and decreased quality of life (4). Several studies have explored the natural history of PPF, including the change in pulmonary function, survival and risk factors for mortality (5–7). However, the results varied greatly according to different diagnostic criterion of PPF.

Recently, nintedanib and pirfenidone have been demonstrated to slow the decline of forced vital capacity (FVC) in patients with PPF (8,9). It is therefore important to identify the progressive phenotype for the precise

treatment. Till now, researchers have proposed three diagnostic criteria for PPF, which assess the progression in the preceding 6 (8), 12 (10,11) and 24 (5-7,9) months respectively (12). And the international working group of IPF has proposed a standard definition of PPF (13). However, there have been limited data on the comparison of the three criteria using the same cohort data. The goal of this study was to compare the three different diagnostic criteria. We present this article in accordance with the STROBE reporting checklist (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-481/rc>).

Methods

Study population

We reviewed the fibrotic ILD cases diagnosed at People's Hospital of Deyang City, from January, 2016 to December, 2021. Adult patients with diagnosis of ILD, were included in this analysis. Patients with diagnosis of IPF or with antifibrotic therapy more than 6 months were excluded from the cohort. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of People's Hospital of Deyang City (No. 2023-04-084-K01) and informed consent was taken from all the patients.

Diagnostic criteria

ILD diagnoses were made by multidisciplinary discussion using established diagnostic criteria. The usual interstitial pneumonia (UIP) pattern defines the typical changes of

IPF in radiology and pathology. However, it's not a clinical diagnosis. IPF was diagnosed according to the recent guidelines (13), with probable IPF defined as a diagnosis of IPF by multidisciplinary discussion. Patients with IPF and probable IPF were excluded for the assessment of progressive fibrosing. PPF was diagnosed by three criteria (*Table 1*): (I) the 0.5-year criterion: in the preceding 6 months, an absolute decline in FVC% of over 5% or worsening respiratory symptoms not due to cardiac, pulmonary, vascular, or other causes (8); (II) the 1-year criterion: PPF was defined with at least two of the three criteria: worsening respiratory symptoms; in the preceding 12 months, an absolute decline in predicted FVC% of over 5% or an absolute decline in predicted percent diffusing capacity of the lungs for carbon monoxide (DL_{CO}%) of 10%; increased fibrosis on high-resolution computed tomography (HRCT) scan (13); (III) the 2-year criterion: in the preceding 24 months, an absolute decline in predicted FVC% of over 10%, or an absolute decline in predicted FVC% of 5–10% with worsening respiratory symptoms or increased fibrosis on HRCT scan, or worsening respiratory symptoms and increased fibrosis on HRCT (9). Connective tissue disease-associated ILD (CTD-ILD) was diagnosed in collaboration with a rheumatologist using diagnostic criteria where available.

Data collection

Baseline timepoint for PPF patients was defined as the time when the patients started the assessment of progressive fibrosing. Demographic data, including age and sex, and smoking history were recorded at the first clinic visit. Longitudinal data included pulmonary function test (PFT, including FVC% and DL_{CO}%), six minutes walking distance (6MWD), HRCT and University of California, San Diego Shortness of Breath Questionnaire (UCSD-SOBQ), were measured in the follow-up visits. PFT and 6MWD were conducted out according to the relevant guidelines. There might be bias because of the losing follow up. So, we compared the baseline characteristics of patients with 6, 12, 24 months follow up to patients without 6, 12, 24 months follow up, respectively. UIP pattern on HRCT was defined as basal and subpleural predominant honeycombing opacities associated with traction bronchiectasis (13). HRCT was evaluated by two experienced radiologists separately. The standard of assessment is shown in *Figure S1*. The controversial cases were discussed, until reaching a consensus.

Highlight box

Key findings

- Both the 1- and 2-year criterion are the reasonable choice to define progressive pulmonary fibrosis (PPF).

What is known and what is new?

- The 1-year criterion is the standard definition of PPF.
- Our study demonstrated that the 2-year criteria had similar diagnostic efficiency with the 1-year criteria.

What is the implication, and what should change now?

- The clinical practitioners should make flexible application with the 1- and 2-year criteria.
- The 0.5-year standard was inefficient to differentiate the PPF from interstitial lung disease, which should be carefully used in future research and clinical practice.

Table 1 The three diagnostic criteria of PPF

Domain	5-year	1-year	2-year
Symptoms	Worsening respiratory symptoms	Worsening respiratory symptoms	Worsening respiratory symptoms
Pulmonary function	An absolute decline in FVC% over 5%	An absolute decline in predicted FVC% over 5% or an absolute decline in DL _{CO} % of 10%	An absolute decline in predicted FVC% over 10%, or an absolute decline in predicted FVC% of 5–10%
Radiology	–	Increased fibrosis on HRCT	Increased fibrosis on HRCT

PPF, progressive pulmonary fibrosis; FVC, forced vital capacity; DL_{CO}, diffusing capacity of the lung for carbon monoxide; HRCT, high-resolution computed tomography.

UCSD-SOBQ is a domain-specific patient-reported measurement. It consists 24 questions assessing the severity of breathlessness in daily activities. Each question requests an answer scored from 0 to 5, representing 'no dyspnea' to 'maximally'. The sum of the scores indicates the severity of dyspnea (14), with higher scores representing worse condition of dyspnea. We used 8 points as the minimal important difference of UCSD-SOBQ, which was derived from patients with IPF (15).

Statistical analysis

Quantitative data were presented as mean ± standard deviation or median (interquartile range); the enumeration data were presented as number (percent); For normally distributed data, one-way ANOVA was used for multi-group comparisons, and then Bonferroni's correction was adopted for the ex-post test. An independent sample *t*-test was used for two-group comparisons. *P*<0.05 was used to indicate statistical significance. All analyses were performed using Stata version 16 (StataCorp LLC, TX, USA).

Survival analysis

Survival time was defined from the date of baseline to the date of death or lung transplantation. Patients were censored at the time of last clinic visit, or initiation of antifibrotic treatment. Kaplan-Meier was used to display the survival time in patients with PPF. Log-rank test was used to compare the survival time in sub-group analysis. Cox regression was performed to determine risk factors for mortality. First, univariate Cox analyses were performed, followed by the multivariate Cox analysis using the significant risk factors (*P*<0.05) in the univariate analysis. The cutoff value were selected out according to the references (5,16) and the median value of the cohort.

Estimation of FVC% changes

The changes in FVC% was estimated by the mixed-effect model, in which the fixed effects included the time interval for the PFT measurement, three groups of different diagnostic criteria, age, sex, smoking history, baseline FVC% and DL_{CO}%. Then the predicted values of FVC% change were fitted by linear regression, and we also calculated the average change of FVC% in 1 year. For the sensitive analysis, we selected out the patients meeting to 0.5-year criteria but not the 1-year criteria, patients meeting to 2-year criteria but not the 1-year criteria for analysis of survival and PFT measurement.

Results

Baseline data of PPF by the three diagnostic criteria

A total of 2,476 patients diagnosed with non-IPF fibrotic ILD were included (Table S1). We identified 246 PPF patients by 0.5-year standard, 154 patients by 1-year standard and 281 patients by 2-year standard (Figure 1). Among them, 95% patients (*n*=147) in 1-year group were also included in 2-year group. In contrast, there were only 123 patients both in 0.5-year (50%) and 2-year (44%) group, and 83 patients both in 0.5-year (34%) and 1-year (54%) group. There were no significant differences of baseline characteristics between patients with and without 6-month PFT data (Table S2), with and without 12-month PFT data (Table S3), with and without 24-month PFT data (Table S4).

Then we compared clinical diagnosis, demographic and PFT data of the three groups of patients (Table 2). Specifically, 0.5-year standard included more patients with CTD-ILD [other autoimmune-ILD, 0.5-year (33%) *vs.* 2-year (21%), *P*<0.05]. As a result, fewer patients in 0.5-year group had UIP pattern on HRCT (26% *vs.* 47–




Figure 1 Number of patients by the three different criteria.

49%, $P < 0.05$). The interval time between diagnosis of ILD and diagnosis of PPF were 11, 19, 12 months for 0.5-, 1-, and 2-year groups, respectively. These results indicated that 2- and 1-year standard identified patients with similar clinical characteristics, which were different from the patients in 0.5-year group.

Estimated changes in FVC%

We used mixed effect model to evaluate the factors affecting lung function decline. In the model, we evaluated influences of fixed effects on changes of FVC%, which included

Table 2 Compare the baseline characteristics between the three groups of PPF

Variable	0.5-year	1-year	2-year
Sample size	246	154	281
Unclassifiable ILD	45 (18%)	37 (24%)	58 (21%)
HP	25 (10%)	18 (12%)	41 (15%)
Other ILD	34 (14%)	22 (14%)	45 (16%)
CTD-ILD	142 (58%)	77 (50%)	137 (49%)
Rheumatoid arthritis-ILD	34 (14%)	19 (12%)	36 (13%)
Scleroderma-ILD	28 (11%)	21 (14%)	43 (15%)
Other autoimmune-ILD	80 (33%)	37 (24%)	58 (21%) [#]
Age, years	62±11	64±12	63±12
Male sex	107 (43%)	66 (43%)	112 (40%)
Ever-smoker	148 (60%)	104 (68%)	184 (65%)
Smoking pack-years	17 [5–36]	15 [7–29]	17 [7–35]
FVC, %-predicted	73±20	76±19	75±19
DL _{CO} , %-predicted	55±18	59±20	58±19
6MWD, meters	430±130	412±119	429±113
UCSD-SOBQ total score	39±25	42±25	39±24
UIP pattern on HRCT	65 (26%)	73 (47%)*	158 (49%) [#]
Begin with diagnosis [†]	113 (46%)	75 (49%)	165 (59%) [#]
Time from diagnosis (months) [‡]	11 [7–19]	19 [8–30]	12 [7–24]
Time interval of evaluation (months) [§]	4.3±1.1	7.9±2.6	14.7±6.2

Data are shown as number (%), mean ± standard deviation, or median (interquartile range). *, $P < 0.05$ the group of 1-year compared with the group of 0.5-year; [#], $P < 0.05$ the group of 2-year compared with the group of 0.5-year; [†], the number of patients who begin the assessment of progression at the time of clinical diagnosis; [‡], mean time (months) from the time of clinical diagnosis to the time of starting the assessment of progression; [§], mean time (months) between the two measurements for assessing progression. PPF, progressive pulmonary fibrosis; ILD, interstitial lung disease; HP, hypersensitivity pneumonitis; CTD-ILD, connective tissue disease-associated ILD; FVC, forced vital capacity; DL_{CO}, diffusing capacity of the lung for carbon monoxide; 6MWD, 6-minute walk distance; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire; UIP, usual interstitial pneumonia; HRCT, high-resolution computed tomography.




Figure 2 Survival rates and changes in FVC%. FVC, forced vital capacity.

time interval for the PFT measurement, age, sex, smoking history, baseline FVC% and DL_{CO}%. Only time interval for PFT measurement was correlated with FVC% change (Figure 2, $P < 0.001$). The average annual change in FVC% was -1.0% (95% CI: -0.4% , -1.6%) in 0.5-year group, -2.7% (95% CI: -1.8% , -3.5%) in 1-year group, and -4.1% (95% CI: -3.5% , -4.5%) in 2-year group.

Survival of PPF

The survival time of the three groups is displayed in Figure 2. All three groups of patients didn't reach the medium survival time in the 4-year follow up. The 2-, 3-, and 4-year survival rates after diagnosis of progressive fibrosis were 83%, 72%, and 62% in 2-year group, 74%, 66%, and 66% in 1-year group, 85%, 76%, and 74% in 0.5-year group.

For further comparison, we selected out the patients meeting to 0.5-year criteria but not the 1-year criteria ($n=154$), and compared these patients with group of 1-year (Figure 3). Patients in 0.5-year group had higher survival rate ($P=0.004$), and milder decrease of FVC% ($P < 0.001$) compared with 1-year group. Then the similar analyses were conducted between 2-year and 1-year group. Patients in group of 2-year had higher survival rate ($P=0.02$), and milder decrease of FVC% ($P=0.002$) compared with 1-year group. However, at time of the 4th year, there was similar survival rate and FVC% changes in group of 2-year

and 1-year. Besides, compared with group of 1-year, group of 2-year had 1.59% less decline of FVC%. But, the decline of FVC% was 6.53% less in group of 0.5-year, compared with 1-year group. In conclusion, the 1- and 2-year standard included the patients with the similar survival rates and similar FVC descent speed, which were worse than the 0.5-year standard.

Risk factors for mortality of PPF

We performed the univariate Cox regression in patients with PPF (Table 3), and found four risk factors correlated with mortality, including baseline FVC% (HR 3.4, 95% CI: 1.9–6.1, $P < 0.001$), baseline DL_{CO}% (HR 7.3, 95% CI: 2.8–18.7, $P < 0.001$), change of UCSD-SOBQ scores (HR 5.3, 95% CI: 1.2–22.6, $P=0.02$) and smoking history (HR 2.1, 95% CI: 1.1–3.8, $P=0.02$). In multivariate analysis, only baseline DL_{CO}% $< 50\%$ was correlated with mortality, with a hazard ratio of 3.4 (95% CI: 1.1–10.6, $P=0.03$).

Survival analysis of subgroups

We further compared the survival of subgroups divided by the pre-selected risk factors (Figure 4). The 4-year survival was worse for patients with baseline FVC% $< 60\%$ ($P < 0.001$) and baseline DL_{CO}% $< 50\%$ ($P < 0.001$) compared to patients with higher baseline PFT. And patients with changed UCSD-SOBQ < 8 ($P=0.01$) had higher survival




Figure 3 Compare the survival rates and changes in FVC% of three groups of patients. FVC, forced vital capacity.

Table 3 Factors associated with mortality using 2-year standard (n=281)

Variable	Univariate		Multivariate	
	HR (95% CI)	P value	HR (95% CI)	P value
Baseline FVC% <60%	3.4 (1.9–6.1)	<0.001	1.6 (0.6–4.2)	0.30
Baseline DL _{CO} % <50%	7.3 (2.8–18.7)	<0.001	3.4 (1.1–10.6)	0.03
UIP pattern	1.3 (0.7–2.4)	0.52	–	–
Increase of UCSD-SOBQ >8	5.3 (1.2–22.6)	0.02	3.2 (0.7–13.8)	0.13
Non-CTD vs. CTD	1.0 (0.6–1.6)	0.92	–	–
Smoked	2.1 (1.1–3.8)	0.02	1.8 (0.6–5.1)	0.26
Age [†]	1.0 (0.8–1.3)	0.89	–	–
GERD	0.7 (0.4–1.3)	0.26	–	–

[†], age was stratified by 10 years old. FVC, forced vital capacity; DL_{CO}, diffusing capacity of the lung for carbon monoxide; UIP, usual interstitial pneumonia; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire; CTD, connective tissue disease; GERD, gastroesophageal reflux disease.

rate than those with greater changed UCSD-SOBQ scores. When analyzed by smoking history, the survival at 4-year was higher for patients without smoking history (P=0.02)

compared with patients with smoking histories. There was no difference in survival rate between CTD and non-CTD patients (Figure S2).




Figure 4 Comparison of survival rates in subgroups. (A) Comparison of survival rates when patients are divided into two groups by baseline FVC% over or less than 60%. (B) Comparison of survival rates when patients are divided into two groups by baseline DL_{CO}% over or less than 50%. (C) Comparison of survival rates when patients are divided into two groups by changes in UCSD-SOBQ over or less than 8. (D) Comparison of survival rates when patients are divided into two groups by smoking history. FVC, forced vital capacity; DL_{CO}, diffusing capacity of the lung for carbon monoxide; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire.

Discussion

It is vital to distinguish PPF from fibrotic ILDs, given the beneficial effect of antifibrotic therapy for PPF (8,9). However, there are limited data on the comparison of different diagnostic criteria for PPF. We demonstrated in a large and diverse population of fibrotic ILD that the 1- and 2-year standard were superior than the 0.5-year standard to identify PPF in patients with non-IPF fibrotic ILD, and baseline DL_{CO}% is the independent predictor of mortality for PPF. These findings suggest that both the 1- and 2-year criterion are appropriate to use in future clinical trials, and also has potential utility in routine clinical practice to guide the use of antifibrotic agents.

The 2-year criterion was used most widely (5-7,17) since it was proposed in the INBUILD trial (9). Compared with 2-year criterion, the 0.5-year criterion sets a lower threshold (5%) of FVC% change. It may include patients

with temporary deterioration on PFT, particularly for those who experience the onsets of autoimmune inflammation in patients with CTD-ILD or IPAF. These patients are not traditionally-defined progressive fibrosing. In this study, the 0.5-year standard included 58% patients with CTD-ILD, which was more than the other two groups. Besides, the 1- and 2-year criteria integrated the symptom, PFT and radiology, which gave a comprehensive evaluation of disease progression. Above all, both the 1- and 2-year criterion are appropriate to distinguish the progressive phenotype from fibrotic ILD.

From our results, patients in 1- and 2-year group had the similar trajectory of PFT decline and survival. And, almost all patients (95%) identified by 1-year standard were also in 2-year group. However, there were 47.7% of patients in 2-year group who were not diagnosed by 1-year criteria. Compared with the 1-year standard, the 2-year standard prolongs the time of assessment, it raises

the opportunity to recruit more patients, as some patients took the PFT test with a time interval of over 1 year, which made some patients with disease progression missing the diagnosis of PPF. Therefore, the 1-year standard included fewer patients than the 2-year criteria. As the 1-year criteria has been proposed as the standard diagnostic criteria to identify PPF, the clinical practitioners should make flexible application with the 1- and 2-year criteria, especially for those meeting the 2-year standard, but not the 1-year standard, who take a certain portion of ILD patients in the real-world situation of China.

There are also disadvantages for the current diagnostic criteria. There is usually a long time between the timepoint when the patients start decline of in the performance PFT and the timepoint when they are diagnosed with progressive fibrosis. In our cohort the mean time for the assessment was 7.9 months for 1-year criterion, and 14.7 months for 2-year criterion, which indicates that the treatment is usually initiated after the course when FVC decline has happened, and the pathological damage has already occurred. In order to make earlier and more precise identification of PPF, there are two suggestions for the future research. First, 0.5-year standard has the potential to make earlier diagnosis, and baseline $DL_{CO}\%$ $<50\%$ can be set as one restricted condition to enable 0.5-year standard to identify progressive phenotype more precisely. However, additional studies would be needed to validate any changes to the current criterion. Second, there is urgent need to develop new markers for progressive fibrosing. With the application of artificial intelligence in radiology, some studies have already shown that imaging parameters might be able to recognize progressive tendencies earlier than the traditional parameters (18,19). It would be a promising direction to develop radiological marker by artificial intelligence or biological marker from broncho alveolar lavage fluid.

Baseline demographic characteristics of our cohort are generally similar to the patients from the placebo arm of INBUILD study (9). However, compared with INBUILD, we included more patients with CTD-ILD (49% *vs.* 27%). Accordingly, our cohort had fewer patients with UIP pattern (49% *vs.* 62%), and our 2-year group had higher FVC% (71% *vs.* 69%) and $DL_{CO}\%$ (58% *vs.* 48%) than INBUILD placebo group. The annual decline in FVC% (4%) of our cohort was comparable with that in IPF patients (-2.1% in 24 weeks) (20), but smaller than the raw data (7%) without adjustment from a precious PPF cohort (21).

The 4-year survival rate in our cohort was 62%, which was lower than results from two previous studies: 80% for

3-year survival rate (21) and 77.1% for 4-year survival rate (5). Our cohort, together with other two PPF cohorts, did not reach the medium survival time with 4-, 5- and 7-year follow up respectively. In contrast, the medium survival time of IPF is 3–5 years according to previous reports (22,23). These data suggested that the change in FVC% was similar in patients with IPF and patients of PPF, but the overall survival of PPF was better than that of IPF.

Robust predictive risk factors are vital for early identification of progressive fibrosing. For PPF, the previous study has demonstrated that FVC% decline is correlated with mortality in the one year after diagnosis (6). Our study demonstrates that baseline FVC% and $DL_{CO}\%$ are correlated with post-diagnosis mortality for PPF. Among them, the baseline $DL_{CO}\%$ is an independent predictor for mortality. Consistent with our results, the FVC% and $DL_{CO}\%$ have been demonstrated as important predictors for mortality of other types of ILDs, as evidenced by other studies spanning IPF (24–27), systemic sclerosis-associated ILD (28–30), unclassifiable ILD (31,32) and HP (33,34). These data indicate that regular PFT measurement is important to monitor the disease progression in patients with fibrotic ILD.

Our study has the following limitations related to its retrospective and monocentric design. First, patients were enrolled from a single center, and confirmation of these findings with multicenter data and other populations would be beneficial. Second, the longitudinal data were not collected with fixed time interval, the criteria for disease progression could only be assessed against available data. However, there were no missing survival data, still allowing the robust survival analysis. Third, we included the patients with antifibrotic therapy within 6 months, which might impact on analysis of survival and pulmonary function. However, we reviewed the raw data of our cohort and found that only 11 patients (nintedanib 9; pirfenidone 2) received the antifibrotic therapy. Among them, 6 patients were included in the PPF group (all three criteria). The average time of the antifibrotic treatment was 2.6 (± 1.0) months. Besides, these patients initiated the antifibrotic therapy after they were evaluated by the criteria of PPF, and they had no recheck data of pulmonary function during the time of antifibrotic therapy. As a result, the antifibrotic therapy had very small impact on our results. Finally, our data lack detailed information on treatment of immunosuppressants, which may influence the prognosis of PPF. Although, there were limited number of patients (15%) taking immunosuppressive agents.

Conclusions

In conclusion, this study compared the three diagnostic criteria for PPF using a large and heterogeneous population of patients with fibrotic ILD, and demonstrated the DL_{CO}% at baseline is an independent predictor of mortality in patients with PPF. In the current situation, both the 1- and 2-year criterion are the reasonable choices for diagnosis in research and clinical practice.

Acknowledgments

Funding: None.

Footnote

Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-481/rc>

Data Sharing Statement: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-481/dss>

Peer Review File: Available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-481/prf>

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <https://jtd.amegroups.com/article/view/10.21037/jtd-23-481/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Ethics Committee of People's Hospital of Deyang City (No. 2023-04-084-K01) and informed consent was taken from all the patients.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the

formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2013;188:733-48.
2. George PM, Spagnolo P, Kreuter M, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respir Med* 2020;8:925-34.
3. Olson A, Hartmann N, Patnaik P, et al. Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. *Adv Ther* 2021;38:854-67.
4. Spagnolo P, Distler O, Ryerson CJ, et al. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). *Ann Rheum Dis* 2021;80:143-50.
5. Nasser M, Larrieu S, Si-Mohamed S, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). *Eur Respir J* 2021;57:2002718.
6. Brown KK, Martinez FJ, Walsh SLF, et al. The natural history of progressive fibrosing interstitial lung diseases. *Eur Respir J* 2020;55:2000085.
7. Wuyts WA, Papiris S, Manali E, et al. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach. *Adv Ther* 2020;37:3246-64.
8. Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med* 2020;8:147-57.
9. Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med* 2019;381:1718-27.
10. Solomon JJ, Danoff SK, Goldberg HJ, et al. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease. *Adv Ther* 2019;36:3279-87.
11. Hoffmann-Vold AM, Allanore Y, Alves M, et al. Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. *Ann Rheum Dis* 2021;80:219-27.
12. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing

- interstitial lung disease. *Respir Res* 2020;21:32.
13. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2022;205:e18-47.
 14. Eakin EG, Resnikoff PM, Prewitt LM, et al. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. *Chest* 1998;113:619-24.
 15. Swigris JJ, Han M, Vij R, et al. The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. *Respir Med* 2012;106:1447-55.
 16. Nasser M, Larrieu S, Boussel L, et al. Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). *Respir Res* 2021;22:162.
 17. Hoffmann-Vold AM, Weigt SS, Saggar R, et al. Endotype-phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease. *EBioMedicine* 2019;50:379-86.
 18. Wu X, Yin C, Chen X, et al. Idiopathic Pulmonary Fibrosis Mortality Risk Prediction Based on Artificial Intelligence: The CTPF Model. *Front Pharmacol* 2022;13:878764.
 19. Yang P, Luo Q, Wang X, et al. Comprehensive Analysis of Fibroblast Activation Protein Expression in Interstitial Lung Diseases. *Am J Respir Crit Care Med* 2023;207:160-72.
 20. Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* 2016;194:711-8.
 21. Faverio P, Piluso M, De Giacomi F, et al. Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. *Respiration* 2020;99:838-45.
 22. Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *Am J Respir Crit Care Med* 2018;198:e44-68.
 23. Krauss E, Tello S, Wilhelm J, et al. Assessing the Effectiveness of Pirfenidone in Idiopathic Pulmonary Fibrosis: Long-Term, Real-World Data from European IPF Registry (eurIPFreg). *J Clin Med* 2020;9:3763.
 24. Paterniti MO, Bi Y, Rekić D, et al. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. *Ann Am Thorac Soc* 2017;14:1395-402.
 25. Jo HE, Glaspole I, Grainge C, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. *Eur Respir J* 2017;49:1601592.
 26. Snyder L, Neely ML, Hellkamp AS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. *Respir Res* 2019;20:105.
 27. Doubková M, Švancara J, Svoboda M, et al. EMPIRE Registry, Czech Part: Impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. *Clin Respir J* 2018;12:1526-35.
 28. Goh NS, Hoyles RK, Denton CP, et al. Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. *Arthritis Rheumatol* 2017;69:1670-8.
 29. Sánchez-Cano D, Ortego-Centeno N, Callejas JL, et al. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group. *Rheumatol Int* 2018;38:363-74.
 30. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. *Ann Rheum Dis* 2010;69:1809-15.
 31. Ryerson CJ, Urbania TH, Richeldi L, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. *Eur Respir J* 2013;42:750-7.
 32. Krauss E, El-Guelai M, Pons-Kuehnemann J, et al. Clinical and Functional Characteristics of Patients with Unclassifiable Interstitial Lung Disease (uILD): Long-Term Follow-Up Data from European IPF Registry (eurIPFreg). *J Clin Med* 2020;9:2499.
 33. Mooney JJ, Elicker BM, Urbania TH, et al. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. *Chest* 2013;144:586-92.
 34. Gimenez A, Storrer K, Kuranishi L, et al. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. *Thorax* 2018;73:391-2.

Cite this article as: Chen T, Zeng C. Compare three diagnostic criteria of progressive pulmonary fibrosis. *J Thorac Dis* 2024;16(2):1034-1043. doi: 10.21037/jtd-23-481




Figure S1 The typical images of HRCT assessment. HRCT, high-resolution computed tomography.

Table S1 Baseline characteristics of total cohort

Variable	Value
Total sample size	2,476
CTD-ILD	1,241 (50%)
Unclassifiable ILD	597 (24%)
HP	235 (9%)
Other ILD	403 (16%)
Age, years	60±14
Male sex	1,019 (41%)
Ever-smoker	1,388 (56%)
Smoking pack-years	18 [7–34]
FVC, %-predicted	75±20
DL _{CO} , %-predicted	60±20
6MWD, meters	420±127
UCSD-SOBQ total score	38±28

Data are shown as number (%), mean ± standard deviation, or median (interquartile range). 6MWD, 6-minute walk distance; CTD-ILD, connective tissue disease-associated ILD; DL_{CO}, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; HP, hypersensitivity pneumonitis; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire.

Table S2 Baseline characteristics of patients with and without 6-month follow-up

Variable	Patients with 6-month data available	Patients without 6-month data available	P
Total patients	682	1,794	–
Age, years	58±13	60±14	0.001
Male sex	285 (42%)	734 (41%)	0.652
Ever-smoker	396 (58%)	992 (55%)	0.179
Smoking pack-years	15 [5–31]	19 [7–34]	–
FVC, %-predicted	72±19	77±21	<0.001
DL _{CO} , %-predicted	57±19	61±21	<0.001
6MWD, meters	430±129	415±125	0.109
UCSD-SOBQ total score	38±26	37±27	0.346

Data are shown as number (%), mean ± standard deviation, or median [interquartile range]. 6MWD, 6-minute walk distance; DL_{CO}, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire.

Table S3 Baseline characteristics of patients with and without 12-month follow-up

Variable	Patients with 12-month data available	Patients without 12-month data available	P
Total patients	1,125	1,351	–
Age, years	58±13	60±14	0.002
Male sex	460 (41%)	559 (41%)	1.000
Ever-smoker	640 (57%)	748 (55%)	0.318
Smoking pack-years	16 [6–31]	20 [7–35]	–
FVC, %-predicted	75±19	76±21	0.248
DL _{CO} , %-predicted	60±20	60±21	0.720
6MWD, meters	434±122	402±131	<0.001
UCSD-SOBQ total score	36±25	39±28	0.018

Data are shown as number (%), mean ± standard deviation, or median [interquartile range]. 6MWD, 6-minute walk distance; DL_{CO}, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire.

Table S4 Baseline characteristics of patients with and without 24-month follow-up

Variable	Patients with 24-month data available	Patients without 24-month data available	P
Total patients	1,305	1,171	–
Age, years	59±13	61±14	<0.001
Male sex	528 (40%)	491 (42%)	0.312
Ever-smoker	731 (56%)	657 (56%)	1.000
Smoking pack-years	16 [6–33]	20 [7–35]	–
FVC, %-predicted	75±20	76±21	0.579
DL _{CO} , %-predicted	60±20	59±21	0.285
6MWD, meters	434±123	396±129	<0.001
UCSD-SOBQ total score	35±25	40±28	<0.001

Data are shown as number (%), mean ± standard deviation, or median [interquartile range]. 6MWD, 6-minute walk distance; DL_{CO}, diffusing capacity of the lung for carbon monoxide; FVC, forced vital capacity; UCSD-SOBQ, University of California, San Diego Shortness of Breath Questionnaire.




Figure S2 Compare survival rate of CTD with non-CTD patients. CTD, connective tissue disease.